Cover Image

經皮吸收貼片的全球市場及開發平台(管線)分析 (2015年)

Global Transdermal Patch Market & Pipeline Insight 2015

出版商 KuicK Research 商品編碼 324804
出版日期 內容資訊 英文 300 Pages
商品交期: 最快1-2個工作天內
Back to Top
經皮吸收貼片的全球市場及開發平台(管線)分析 (2015年) Global Transdermal Patch Market & Pipeline Insight 2015
出版日期: 2015年02月24日 內容資訊: 英文 300 Pages

和其他醫療品市場相同,經皮貼片領域上也在持續進行著研究開發 (R&D) 活動,雖然有助於提升患者的QoL (生活品質),但仍僅實際活用於部分適應症。但也正因如此,製藥企業更加致力投入R&D活動,經皮貼片適用疾病也多元化地擴及禁煙、疼痛管理、帕金森氏症、老年癡呆症、ADHD等各領域,全球市場今後展望也相當樂觀。

本報告提供全球各國經皮吸收貼片市場趨勢,及開發平台產品的開發情形相關分析,提供經皮吸收貼片的特性和作用機制,整體市場結構·趨勢,開發中產品的目前開發情形,產品單位 (計92產品) 之詳細開發情形,已上市產品 (計45產品) 銷售情形,今後的市場方向性等資訊,為您概述為以下內容。

第1章 經皮吸收貼片的概要

第2章 經皮吸收貼片的種類

  • 單層式/多層式的藥物黏劑
  • 儲液型貼片
  • 基質型貼片
  • 蒸氣貼片
  • 主動/被動貼片

第3章 經皮吸收貼片的藥物遞送機制

第4章 經皮吸收貼片的優點

第5章 經皮吸收貼片的全球市場展望

  • 目前市場方案
  • 各地區的趨勢
  • 經皮吸收貼片的臨床實驗平台概況

第6章 經皮吸收貼片的全球市場動態

  • 有助於市場的指標
  • 商業化時的課題

第7章 經皮吸收貼片的全球市場未來展望

第8章 經皮吸收貼片的臨床實驗平台:各企業·各適應症·代 (Phase) 別

  • 不明
  • 研究階段
  • 前臨床階段
  • 臨床階段
  • 第一階段
  • 第I/II相
  • 第二階段
  • 第三階段
  • 認證前
  • 已認證

第9章 已上市的M經皮吸收貼片:各企業·各適應症

第10章 臨床實驗延期·中斷的經皮吸收貼片的開發中產品:各企業·各適應症·Phase別

  • 無開發資訊
  • 臨床實驗中斷
  • 市場撤退
  • 臨床實驗延期

第11章 競爭環境

  • 3M Pharmaceuticals
  • Actavis
  • Ethical Holdings
  • GalaxoSmithKline
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • Proctor & Gamble
  • ProStrakan
  • UCB pharmaceuticals
  • Vaxxas pharmaceutical



Technological progress is continuously increasing allowing pharmaceutical companies to develop newer products with higher pharmacological benefits. Transdermal patches are extension of their continuous efforts due to which several patients have been able to improve quality of life. This market segment has yet to be tapped as only few disease indications are being covered under their treatment. Pharmaceutical companies are increasing their investments in research and development segment to introduce novel products in market. Significant progress has been made in past several decades giving rise to presence of myriad of products in global market. They are far better than their predecessors and coming products are expected to be better than existing transdermal patches. As a result, more number of patients are expected to be opting for transdermal patches in their therapeutic regime.

Utilization of transdermal patch varies from region to region due to which their market is diffused in nature. In both industrially developed and under developed countries their consumption is increasing significantly in past few years. US is one of the largest transdermal patch market across the globe followed by Europe. Investment in research and development allows the continuous entry of new products in US market due to which it has largest market shares across the globe. It is pioneer in this field and first patch was introduced in 1979 to treat motion sickness after its wide spread acceptance patches for angina, high blood pressure and hormone replacement therapy were introduced in US market. Over the year newer categories like smoking cessation, pain management, Parkinson's disease, Alzheimer's disease, ADHD and may others disease indications were added resulting in increased market size.

Clinical pipeline for transdermal patches is becoming strong and various novel therapeutics are at different stages of clinical trials which would enter in market in coming years. It is happening because pharmaceutical companies have identified their commercial potential due to which they are investing more toward research and development segment. Orally administrated drugs are not suitable for all patients as they have gastric reflex problem or may have other gastrointestinal diseases due to which bioavailability is limited. On the other, in blood they may interact with other substance causing reduced pharmacological effects. All these problems are not encountered by patients using the transdermal patches.

New principles are being deciphered and increasing emphasis on including more diseases treatment by transdermal patches is imperative for better health. Owing to increasing disease incidences, it has become necessary to take necessary steps to introduce innovative transdermal patches in global market. Oncology and autoimmune diseases are still untouched by them due to which significant opportunities are left untapped. Technological advancements may allow the investigators to develop products having high safety and efficacy levels along with minimized side effects but it will take some time. On the other hand, nicotine patches and female contraceptive patches are highly developed and forms largest categories of transdermal patch segment. Disease indications will be increased in coming years and advancements in polymer science is expected to increase the innovation rates. With all these developments, the future of transdermal patch market seems to be optimistic.

“Global Transdermal Patch Market & Pipeline Insight 2015” Report Highlights:

  • Mechanism of Transdermal Patch Drug Delivery
  • Global Transdermal Patch Market Outlook
  • Transdermal Patch Clinical Pipeline by Company, Indication & Phase
  • Transdermal Patches in Clinical Pipeline: 96
  • Marketed Transdermal Patches: 45
  • Global Transdermal Patch Market Future Prospects

Table of Contents

1. Introduction to Transdermal Patch

2. Types of Transdermal Patches

  • 2.1. Single/ Multiple-Layer Drug-in-Adhesive
  • 2.2. Reservoir Transdermal Patches
  • 2.3. Matrix Based Transdermal Patches
  • 2.4. Vapor Patch
  • 2.5. Active and Passive Patch

3. Mechanism of Transdermal Patch Drug Delivery

4. Advantages of Transdermal Patch

5. Global Transdermal Patch Market Outlook

  • 5.1. Current Market Scenario
  • 5.2. Regional Trends
  • 5.3. Transdermal Patch Clinical Pipeline Overview

6. Global Transdermal Patch Market Dynamics

  • 6.1. Favorable Market Parameters
  • 6.2. Commercialization Challenges

7. Global Transdermal Patch Market Future Prospects

8. Global Transdermal Patch Clinical Pipeline by Company, Indication & Phase

  • 8.1. Unknown
  • 8.2. Research
  • 8.3. Preclinical
  • 8.4. Clinical
  • 8.5. Phase-I
  • 8.6. Phase-I/II
  • 8.7. Phase-II
  • 8.8. Phase-III
  • 8.9. Preregistration
  • 8.10. Registered

9. Marketed Transdermal Patch by Company & Indication

10. Suspended & Discontinued Transdermal Patch Clinical Pipeline by Company, Indication & Phase

  • 10.1. No Development Reported
  • 10.2. Discontinued
  • 10.3. Market withdrawal
  • 10.4. Suspended

11. Competitive Landscape

  • 11.1. 3M Pharmaceuticals
  • 11.2. Actavis
  • 11.3. Ethical Holdings
  • 11.4. GalaxoSmithKline
  • 11.5. Johnson & Johnson
  • 11.6. Novartis
  • 11.7. Pfizer
  • 11.8. Proctor & Gamble
  • 11.9. ProStrakan
  • 11.10. UCB pharmaceuticals
  • 11.11. Vaxxas pharmaceutical

List of Figures

  • Figure 1-1: Steps Involved in Transdermal Permeation
  • Figure 1-2: Ideal Properties of Transdermal Patch
  • Figure 2-1: Types of Commercially Available Transdermal Patch
  • Figure 3-1: Properties of Transdermal Therapeutics
  • Figure 3-2: Components of Transdermal Patch
  • Figure 3-3: Types of Permeation Enhancers
  • Figure 3-4: Schematic Representation of Iontophoresis
  • Figure 3-5: Mechanism of Scopolamine Transdermal Patch
  • Figure 3-6: Mechanism of Nicotine Transdermal Patch
  • Figure 3-7: Mechanism of Female Contraceptive Transdermal Patch
  • Figure 4-1: Issues with Traditional Drug Delivery Methods
  • Figure 4-2: Advantages of Transdermal Patch
  • Figure 4-3: Consistent Drug Supply by Transdermal Patch
  • Figure 5-1: Transdermal Patch Clinical Pipeline by Phase (%), 2015
  • Figure 5-2: Transdermal Patch Clinical Pipeline by Phase (Number), 2015
  • Figure 5-3: No Development Reported in Transdermal Patch Clinical Pipeline by Phase (%), 2015
  • Figure 5-4: No Development Reported in Transdermal Patch Clinical Pipeline by Phase (Number), 2015
  • Figure 5-5: Discontinued Transdermal Patch Clinical Pipeline by Phase (%), 2015
  • Figure 5-6: Discontinued Transdermal Patch Clinical Pipeline by Phase (Number), 2015
  • Figure 6-1: Drivers for Transdermal Patch
  • Figure 6-2: Transdermal Patch Market Commercialization Challenges
Back to Top